08:40 AM EDT, 07/15/2024 (MT Newswires) -- Heron Therapeutics ( HRTX ) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.

Zynrelef will be included under Medicare's Outpatient Prospective Payment System and the Medicare Ambulatory Surgical Center, beginning April 1.

The company said Zynrelef was qualified because it is approved for the treatment of post-operative pain and has the ability to reduce or eliminate the need for opioids.

Zynrelef costs are currently reimbursed by the Centers for Medicare and Medicaid Services under a special payment process that expires on March 31.

Price: 3.3427, Change: +0.10, Percent Change: +3.17